EMA Authorised: Kanjinti (trastuzumab) — Amgen Europe B.V.

View source ↗

Summary

EMA authorises Kanjinti (trastuzumab) for indications including stomach and breast neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Neoplasms
• Stomach Neoplasms

Drugs mentioned

• KANJINTI (TRASTUZUMAB-ANNS)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Amgen Europe B.V.. Decision date: 10/08/2026